• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Imunon Inc.

    6/17/26 4:15:30 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNN alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on June 17, 2026

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    IMUNON, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   52-1256615

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    997 Lenox Drive, Suite 100

    Lawrenceville, NJ 08648-2311

    (Address of principal executive offices) (Zip code)

     

    Imunon, Inc. 2018 Stock Incentive Plan

    (Full title of the plan)

     

    Stacy R. Lindborg

    President and Chief Executive Officer

    997 Lenox Drive, Suite 100

    Lawrenceville, NJ 08648

    (609) 896-9100

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

    Jurgita Ashley

    Thompson Hine LLP

    3900 Key Center

    127 Public Square

    Cleveland, Ohio 44114

    (216) 566-5500

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    On June 16, 2026, the shareholders of Imunon, Inc. (the “Registrant”) approved an amendment to the Imunon, Inc. 2018 Stock Incentive Plan, as amended as of June 16, 2026 (the “Amended Plan”) to increase the number of shares of the Registrant’s common stock, par value $0.01 (the “Common Stock”) that are available for issuance thereunder by 1,000,000 shares. This Registration Statement on Form S-8 is being filed by the Registrant for the purpose of registering an additional 1,000,000 shares of Common Stock, in accordance with the Amended Plan. Pursuant to Instruction E of Form S-8, the contents of the (i) the Form S-8 Registration Statement (File No. 333-291493) filed with the Securities and Exchange Commission (the “Commission”) on November 13, 2025, (ii) the Form S-8 Registration Statement (File No. 333-273923) filed with the Commission on August 11, 2023, (iii) the Form S-8 Registration Statement (File No. 333-266882) filed with the Commission on August 15, 2022, (iv) the Form S-8 Registration Statement (File No. 333-240275) filed with the Commission on July 31, 2020, (v) the Form S-8 Registration Statement (File No. 333-233344) filed with the Commission on August 16, 2019, and (vi) the Form S-8 Registration Statement (File No. 333-225045) filed with the Commission on May 18, 2018 are incorporated by reference herein, except to the extent supplemented, amended or superseded by the information set forth below.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:

     

    1)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 31, 2026;
    2)The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the Commission on May 12, 2026;
    3)The Registrant’s Current Reports on Form 8-K filed with the Commission on January 7, 2026, February 5, 2026, March 23, 2026, May 4, 2026, June 4, 2026, and June 16, 2026, excluding any information furnished in such reports under Item 2.02, Item 7.01 or Item 9.01; and
    4)Description of Securities of the Registrant, incorporated herein by reference to Exhibit 4.8 to the Annual Report on Form 10-K of the Registrant for the fiscal year ended December 31, 2025, together with any amendment or report filed with the Commission for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”). Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, or other information that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    Exhibit
    No.
      Description
         
    4.1   Restated Certificate of Incorporation, dated March 22, 2023, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on March 24, 2023.
         
    4.2   Amendment to the Restated Certificate of Incorporation, dated July 11, 2025, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on July 11, 2025.
         
    4.3   Amendment to the Restated Certificate of Incorporation, dated July 21, 2025, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on July 23, 2025.
         
    4.4   Certificate of Designation of Preferences and Rights of Series A Preferred Stock, dated June 1, 2026, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on June 4, 2026.
         
    4.5   Amended and Restated Bylaws, effective on March 15, 2024, incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on March 18, 2024.
         
    5.1*   Opinion of Thompson Hine LLP.
         
    23.1*   Consent of WithumSmith+Brown, PC.
         
    23.2*   Consent of Thompson Hine LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (set forth on the signature page of this Registration Statement).
         
    99.1   Imunon, Inc. 2018 Stock Incentive Plan, as amended as of June 16, 2026, incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of the Registrant, filed with the Commission on June 16, 2026.
         
    99.2   Form of Incentive Stock Option Grant Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of the Registrant for the quarter ended March 31, 2024.
         
    99.3   Form of Restricted Stock Agreement under the 2018 Stock Incentive Plan, incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of the Registrant for the quarter ended March 31, 2024.
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lawrenceville, State of New Jersey on June 17, 2026.

     

      IMUNON, INC.
         
      By: /s/ Stacy R. Lindborg
        Stacy R. Lindborg, Ph.D.
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Stacy R. Lindborg and Susan Eylward, acting alone or together with another attorney-in-fact, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, and any subsequent registration statements pursuant to Rule 462 of the Securities Act, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Stacy R. Lindborg   President, Chief Executive Officer and Director   June 17, 2026
    Stacy R. Lindborg, Ph.D.   (Principal Executive Officer)    
             
    /s/ Jeffrey W. Church   Chief Financial Officer   June 17, 2026
    Jeffrey W. Church   (Principal Financial and Accounting Officer)    
             
    /s/ Michael H. Tardugno   Executive Chairman of the Board of Directors   June 17, 2026
    Michael H. Tardugno        
             
    /s/ Donald P. Braun   Director   June 17, 2026
    Donald P. Braun, Ph.D.        
             
    /s/ James E. Dentzer   Director   June 17, 2026
    James E. Dentzer        
             
    /s/ Frederick J. Fritz   Director   June 17, 2026
    Frederick J. Fritz        
             
    /s/ Christine A. Pellizzari   Director   June 17, 2026
    Christine A. Pellizzari        

     

     

    Get the next $IMNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMNN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

    On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating unprecedented IL-12 safety profile and extraordinary Phase 2 efficacy LAWRENCEVILLE, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoa

    6/23/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Present at the Life Sciences Investor Forum on June 25th

    LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET. DATE: Thursday, June 25th, 2026TIME: 12:00 p.m. ETWebcast Registration Link HereAvailable for 1x1 meetings: Schedule 1x1 Meetings HERE This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event liv

    6/22/26 4:15:00 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    SEC Filings

    View All

    SEC Form S-8 filed by Imunon Inc.

    S-8 - Imunon, Inc. (0000749647) (Filer)

    6/17/26 4:15:30 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Imunon Inc.

    8-K - Imunon, Inc. (0000749647) (Filer)

    6/16/26 5:30:17 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Imunon Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Imunon, Inc. (0000749647) (Filer)

    6/4/26 8:00:40 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Braun Donald P bought $29,480 worth of shares (25,000 units at $1.18), increasing direct ownership by 4,188% to 25,597 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    1/28/25 4:18:24 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Lindborg Stacy bought $24,500 worth of Imunon Common Stock (25,000 units at $0.98), increasing direct ownership by 10% to 264,166 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:03:50 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman of Board Tardugno Michael H bought $25,750 worth of Imunon Common Stock (25,000 units at $1.03), increasing direct ownership by 8% to 353,346 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:01:30 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman of Board Tardugno Michael H was granted 4,629 shares, increasing direct ownership by 36% to 17,467 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/23/26 7:59:08 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Lindborg Stacy was granted 1,803 shares, increasing direct ownership by 34% to 7,038 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/23/26 4:17:54 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman of Board Tardugno Michael H was granted 4,089 shares, increasing direct ownership by 47% to 12,838 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    6/9/26 5:15:53 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Leadership Updates

    Live Leadership Updates

    View All

    IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

    Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

    2/10/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

    Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

    5/8/24 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

    12/11/23 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Imunon Inc.

    SC 13G/A - Imunon, Inc. (0000749647) (Subject)

    11/14/24 12:17:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    8/5/24 11:53:32 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Financials

    Live finance-specific insights

    View All

    IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

    IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported fin

    5/12/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

    LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer. To participate in the call, please dial 800-715-9871 (U.S. and Canada/Toll Free) or 646-307-1963 (U

    5/5/26 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

    LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1

    3/24/26 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care